Pharmaceutical

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma

The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.

Aug 3, 2024 - 04:00
Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma
The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.
Read the original article

Tags:

Previous Article

Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes

Next Article

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA grants approval for Pfizer’s RSV vaccine

FDA grants approval for Pfizer’s RSV vaccine

Aug 22, 2023

Meet the fetal surgeon forging CRISPR’s next frontier: curing diseases in the womb

Meet the fetal surgeon forging CRISPR’s next frontier: ...

Feb 21, 2024

Opinion: STAT readers on what human health care can learn from veterinary medicine and more

Opinion: STAT readers on what human health care can lea...

Feb 17, 2024